康莱特联合介入化疗治疗原发性肝癌的临床研究

A Clinical Study on Kanglaite Combined with Interventional Chemotherapy in the Treatment of Primary Hepatocellular Carcinoma

目的探讨康莱特联合介入化疗治疗原发性肝癌的临床疗效及安全性。方法选取2013年11月~2014年5月我院肿瘤科收治的原发性肝癌患者共97例为研究对象,随机分为对照组和试验组。对照组给予常规介入化疗,试验组采用康莱特联合介入化疗治疗。分别比较两组患者治疗后实体肿瘤缓解率、治疗前后生存质量评分、血清AFP水平和肝功能的变化情况。结果治疗后,试验组的实体肿瘤缓解率、生存质量评分、AFP及肝功能改善率均显著高于对照组,不良反应发生率显著低于对照组,差异均具有统计学意义(P<0.05)。结论与常规介入化疗相比,康莱特联合介入化疗治疗原发性肝癌能显著提高临床疗效和患者的生活质量,并改善患者肝功能。

Objective To investigate the clinical effect and safety of Kanglaite combined with interventional chemotherapy in the treat- ment of primary hepatocellular carcinoma. Methods A total of 97 patients with primary hepatocellular carcinoma were selected from the department of oncology from March 2012 to January 2014 and randomized into two groups. The control group was given conventional inter- ventional chemotherapy, and the test group was given Kanglaite combined with interventional chemotherapy. The rates of remission, changes of quality of life, serum AFP level and improvement of liver function were compared between the two groups. Results The remission rate, Karnofsky score, improvement rate of liver function and AFP of the test group were significantly higher than those of the control group after treatment（P 〈 0.05）, and the incidence of adverse reactions was significantly lower than that of the control group（P 〈 0.05）. Conclusion Com- pared with interventional chemotherapy alone, Kanglaite combined with interventional chemotherapy technique could effectively enhance the clinical efficacy, quality of life and improve the liver function of patients with primary hepatocellular carcinoma.